Sequencing Treatment in Relapsed/Refractory Multiple Myeloma: The Right Treatment at the Right Time for the Right Patient

Sequencing Treatment in Relapsed/Refractory Multiple Myeloma: The Right Treatment at the Right Time for the Right Patient
Sequencing Treatment in Relapsed/Refractory Multiple Myeloma: The Right Treatment at the Right Time for the Right Patient
CME, CPE
Paul G. Richardson, MD
Release Date: October 29, 2018
Expiration Date: October 29, 2019

With many new and emerging drug classes for the treatment of relapsed/refractory multiple myeloma (RRMM), it can be challenging to determine the optimal approach to sequencing treatment for patients with the disease. This activity will compare efficacy and safety data on new and emerging therapies in RRMM and provide strategies for incorporating risk-adapted treatment decisions to optimize patient outcomes.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
Begin, Earn CreditView Only, No CreditGet Certificate